Tinzaparin inhibits VL30 retrotransposition induced by oxidative stress and/or VEGF in HC11 mouse progenitor mammary cells: Association between inhibition of cancer stem cell proliferation and mammosphere disaggregation

Mantziou,Stefania; Markopoulos,Georgios; Thrasyvoulou,Soteroula; Noutsopoulos,Dimitrios; Gkartziou,Foteini; Vartholomatos,Georgios; Tzavaras,Theodore

doi:10.3892/or.2021.8192

Tinzaparin inhibits VL30 retrotransposition induced by oxidative stress and/or VEGF in HC11 mouse progenitor mammary cells: Association between inhibition of cancer stem cell proliferation and mammosphere disaggregation

Authors:
- Stefania Mantziou
- Georgios Markopoulos
- Soteroula Thrasyvoulou
- Dimitrios Noutsopoulos
- Foteini Gkartziou
- Georgios Vartholomatos
- Theodore Tzavaras
View Affiliations

Affiliations: Laboratory of General Biology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece, Molecular Biology Unit, Hematology Laboratory, University Hospital of Ioannina, 45110 Ioannina, Greece
Published online on: September 23, 2021 https://doi.org/10.3892/or.2021.8192
Article Number: 241
Copyright: © Mantziou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tinzaparin is an anticoagulant and antiangiogenic drug with inhibitory properties against tumor growth. VEGF stimulates angiogenesis, while an association between reactive oxygen species (ROS) and angiogenesis is involved in tumor progression. The present study aimed to investigate the effect of tinzaparin on VL30 retrotransposition‑positive mouse HC11 mammary stem‑like epithelial cells, previously reported to be associated with induced mammosphere/cancer stem cell (CSC) generation and tumorigenesis. Under 24 h serum starvation, 15.2% nominal retrotransposition frequency was increased to 29%. Additionally, while treatment with 3‑12 ng/ml VEGF further induced retrotransposition frequency in a dose‑dependent manner (up to 40.3%), pre‑incubation with tinzaparin (2 IU/ml) for 0.5‑4 h reduced this frequency to 18.3% in a time‑dependent manner, confirmed by analogous results in NIH3T3 fibroblasts. Treatment with 10‑40 pg/ml glucose oxidase (GO) for 24 h induced HC11 cell retrotransposition in a dose‑dependent manner (up to 82.5%), while a 3 h pre‑incubation with tinzaparin (1 or 2 IU/ml) elicited a 13.5 or 25.5% reduction in retrotransposition, respectively. Regarding tumorigenic VL30 retrotransposition‑positive HC11 cells, treatment with 2 IU/ml tinzaparin for 5 days reduced proliferation rate in a time‑dependent manner (up to ~55%), and after 3 weeks, disaggregated soft agar‑formed foci, as well as low‑adherent mammospheres, producing single mesenchymal‑like cells with a ~50% reduced retrotransposition. With respect to the VL30 retrotransposition mechanism: While 12 ng/ml VEGF increased the level of VL30 and endogenous reverse transcriptase (enRT) transcripts ~1.41‑ and ~1.16‑fold, respectively, subsequent tinzaparin treatment reduced both endogenous/ROS‑ and VEGF‑induced levels 1.15‑ and 0.40‑fold (VL30) and 0.60‑ and 0.52‑fold (enRT), respectively. To the best of our knowledge, these data demonstrate for the first time, the novel inhibition activity of tinzaparin against ROS‑ and VEGF‑induced VL30 retrotransposition, and the proliferation and/or aggregation of mouse HC11 mammosphere/tumor‑initiating CSCs, thus contributing to the inhibition of VL30 retrotransposition‑induced primary tumor growth.

View Figures

View References

1	Khorana AA and Connolly GC: Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 27:4839–4847. 2009. View Article : Google Scholar : PubMed/NCBI
2	Mandalà M, Falanga A and Roila F; ESMO Guidelines Working Group, : Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 22 (Supp 6):vi85–vi92. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 33:654–656. 2015. View Article : Google Scholar : PubMed/NCBI
4	Dahlbäck B: Blood coagulation. Lancet. 355:1627–1632. 2000. View Article : Google Scholar : PubMed/NCBI
5	Wong NN: Tinzaparin. Heart Dis. 4:331–340. 2002. View Article : Google Scholar : PubMed/NCBI
6	Horton J: Venous thrombotic events in cancer: The bottom line. Cancer Control. 12 (Suppl 1):S31–S37. 2005. View Article : Google Scholar : PubMed/NCBI
7	Scotté F, Rey JB and Launay-Vacher V: Thrombosis, cancer and renal insufficiency: Low molecular weight heparin at the crossroads. Support Care Cancer. 20:3033–3042. 2012. View Article : Google Scholar : PubMed/NCBI
8	Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS and Vredenburgh JJ: Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 95:129–134. 2009. View Article : Google Scholar : PubMed/NCBI
9	Stevenson JL, Choi SH and Varki A: Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 11:7003–7011. 2005. View Article : Google Scholar : PubMed/NCBI
10	Schlesinger M, Roblek M, Ortmann K, Naggi A, Torri G, Borsig L and Bendas G: The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Thromb Res. 133:855–862. 2014. View Article : Google Scholar : PubMed/NCBI
11	Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA and Ali S: Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids? Clin Cancer Res. 13:1562–1570. 2007. View Article : Google Scholar : PubMed/NCBI
12	Alyahya R, Sudha T, Racz M, Stain SC and Mousa SA: Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol. 46:1225–1231. 2015. View Article : Google Scholar : PubMed/NCBI
13	Bauer AT, Suckau J, Frank K, Desch A, Goertz L, Wagner AH, Hecker M, Goerge T, Umansky L, Beckhove P, et al: von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood. 125:3153–3163. 2015. View Article : Google Scholar : PubMed/NCBI
14	Amirkhosravi A, Mousa SA, Amaya M and Francis JL: Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost. 1:1972–1976. 2003. View Article : Google Scholar : PubMed/NCBI
15	Mousa SA and Mohamed S: Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy. Oncol Rep. 12:683–688. 2004.PubMed/NCBI
16	Mousa SA and Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 92:627–633. 2004. View Article : Google Scholar : PubMed/NCBI
17	Pfankuchen DB, Stölting DP, Schlesinger M, Royer HD and Bendas G: Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells. Biochem Pharmacol. 97:147–157. 2015. View Article : Google Scholar : PubMed/NCBI
18	Dimakakos EP, Vathiotis I and Syrigos K: The role of tinzaparin in oncology. Clin Appl Thromb Hemost. 24:697–707. 2018. View Article : Google Scholar : PubMed/NCBI
19	Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB and Frimundt Petersen C: Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep. 14:99–104. 2005.PubMed/NCBI
20	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
21	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
22	Gamperl H, Plattfaut C, Freund A, Quecke T, Theophil F and Gieseler F: Extracellular vesicles from malignant effusions induce tumor cell migration: Inhibitory effect of LMWH tinzaparin. Cell Biol Int. 40:1050–1061. 2016. View Article : Google Scholar : PubMed/NCBI
23	Sudha T, Yalcin M, Lin HY, Elmetwally AM, Nazeer T, Arumugam T, Phillips P and Mousa SA: Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett. 350:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
24	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
25	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
26	Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ and Ellis LM: Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 66:46–51. 2006. View Article : Google Scholar : PubMed/NCBI
27	Hayashida T, Jinno H, Kitagawa Y and Kitajima M: Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011:5914272011. View Article : Google Scholar : PubMed/NCBI
28	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
29	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
30	Cordaux R and Batzer MA: The impact of retrotransposons on human genome evolution. Nat Rev Genet. 10:691–703. 2009. View Article : Google Scholar : PubMed/NCBI
31	Boeke JD, Garfinkel DJ, Styles CA and Fink GR: Ty elements transpose through an RNA intermediate. Cell. 40:491–500. 1985. View Article : Google Scholar : PubMed/NCBI
32	Hancks DC and Kazazian HH Jr: Roles for retrotransposon insertions in human disease. Mob DNA. 7:92016. View Article : Google Scholar : PubMed/NCBI
33	Heidmann T, Heidmann O and Nicolas JF: An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci USA. 85:2219–2223. 1988. View Article : Google Scholar : PubMed/NCBI
34	Georgiou I, Noutsopoulos D, Dimitriadou E, Markopoulos G, Apergi A, Lazaros L, Vaxevanoglou T, Pantos K, Syrrou M and Tzavaras T: Retrotransposon RNA expression and evidence for retrotransposition events in human oocytes. Hum Mol Genet. 18:1221–1228. 2009. View Article : Google Scholar : PubMed/NCBI
35	Goodier JL and Kazazian HH Jr: Retrotransposons revisited: The restraint and rehabilitation of parasites. Cell. 135:23–35. 2008. View Article : Google Scholar : PubMed/NCBI
36	French NS and Norton JD: Structure and functional properties of mouse VL30 retrotransposons. Biochim Biophys Acta. 1352:33–47. 1997. View Article : Google Scholar : PubMed/NCBI
37	Garen A and Song X: Regulatory roles of tumor-suppressor proteins and noncoding RNA in cancer and normal cell functions. Int J Cancer. 122:1687–1689. 2008. View Article : Google Scholar : PubMed/NCBI
38	Markopoulos G, Noutsopoulos D, Mantziou S, Gerogiannis D, Thrasyvoulou S, Vartholomatos G, Kolettas E and Tzavaras T: Genomic analysis of mouse VL30 retrotransposons. Mob DNA. 7:102016. View Article : Google Scholar : PubMed/NCBI
39	Brunmeir R, Lagger S, Simboeck E, Sawicka A, Egger G, Hagelkruys A, Zhang Y, Matthias P, Miller WJ and Seiser C: Epigenetic regulation of a murine retrotransposon by a dual histone modification mark. PLoS Genet. 6:e10009272010. View Article : Google Scholar : PubMed/NCBI
40	Noutsopoulos D, Vartholomatos G, Kolaitis N and Tzavaras T: SV40 large T antigen up-regulates the retrotransposition frequency of viral-like 30 elements. J Mol Biol. 361:450–461. 2006. View Article : Google Scholar : PubMed/NCBI
41	Noutsopoulos D, Markopoulos G, Koliou M, Dova L, Vartholomatos G, Kolettas E and Tzavaras T: Vanadium induces VL30 retrotransposition at an unusually high level: A possible carcinogenesis mechanism. J Mol Biol. 374:80–90. 2007. View Article : Google Scholar : PubMed/NCBI
42	Markopoulos G, Noutsopoulos D, Mantziou S, Vartholomatos G, Monokrousos N, Angelidis C and Tzavaras T: Arsenic induces VL30 retrotransposition: The involvement of oxidative stress and heat-shock protein 70. Toxicol Sci. 134:312–322. 2013. View Article : Google Scholar : PubMed/NCBI
43	Tzavaras T, Eftaxia S, Tavoulari S, Hatzi P and Angelidis C: Factors influencing the expression of endogenous reverse transcriptases and viral-like 30 elements in mouse NIH3T3 cells. Int J Oncol. 23:1237–1243. 2003.PubMed/NCBI
44	Konisti S, Mantziou S, Markopoulos G, Thrasyvoulou S, Vartholomatos G, Sainis I, Kolettas E, Noutsopoulos D and Tzavaras T: H2O2 signals via iron induction of VL30 retrotransposition correlated with cytotoxicity. Free Radic Biol Med. 52:2072–2081. 2012. View Article : Google Scholar : PubMed/NCBI
45	Noutsopoulos D, Markopoulos G, Vartholomatos G, Kolettas E, Kolaitis N and Tzavaras T: VL30 retrotransposition signals activation of a caspase-independent and p53-dependent death pathway associated with mitochondrial and lysosomal damage. Cell Res. 20:553–562. 2010. View Article : Google Scholar : PubMed/NCBI
46	Thrasyvoulou S, Vartholomatos G, Markopoulos G, Noutsopoulos D, Mantziou S, Gkartziou F, Papageorgis P, Charchanti A, Kouklis P, Constantinou AI and Tzavaras T: VL30 retrotransposition is associated with induced EMT, CSC generation and tumorigenesis in HC11 mouse mammary stem-ike epithelial cells. Oncol Rep. 44:126–138. 2020. View Article : Google Scholar : PubMed/NCBI
47	Ball RK, Friis RR, Schoenenberger CA, Doppler W and Groner B: Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J. 7:2089–2095. 1988. View Article : Google Scholar : PubMed/NCBI
48	Williams C, Helguero L, Edvardsson K, Haldosén LA and Gustafsson JA: Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression. Breast Cancer Res. 11:R262009. View Article : Google Scholar : PubMed/NCBI
49	Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK and Winn RA: The soft agar colony formation assay. J Vis Exp. e519982014.PubMed/NCBI
50	Ostertag EM, Prak ET, DeBerardinis RJ, Moran JV and Kazazian HH Jr: Determination of L1 retrotransposition kinetics in cultured cells. Nucleic Acids Res. 28:1418–1423. 2000. View Article : Google Scholar : PubMed/NCBI
51	Xiong Y and Eickbush TH: Origin and evolution of retroelements based upon their reverse transcriptase sequences. EMBO J. 9:3353–3362. 1990. View Article : Google Scholar : PubMed/NCBI
52	Puschendorf M, Stein P, Oakeley EJ, Schultz RM, Peters AH and Svoboda P: Abundant transcripts from retrotransposons are unstable in fully grown mouse oocytes. Biochem Biophys Res Commun. 347:36–43. 2006. View Article : Google Scholar : PubMed/NCBI
53	Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, et al: Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA. 105:14076–14081. 2008. View Article : Google Scholar : PubMed/NCBI
54	White EZ, Pennant NM, Carter JR, Hawsawi O, Odero-Marah V and Hinton CV: Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells. Sci Rep. 10:125052020. View Article : Google Scholar : PubMed/NCBI
55	Merlo GR, Venesio T, Taverna D, Marte BM, Callahan R and Hynes NE: Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene. 9:443–453. 1994.PubMed/NCBI
56	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar : PubMed/NCBI
57	Grugel S, Finkenzeller G, Weindel K, Barleon B and Marmé D: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 270:25915–25919. 1995. View Article : Google Scholar : PubMed/NCBI
58	Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L and Elazar Z: Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 26:1749–1760. 2007. View Article : Google Scholar : PubMed/NCBI
59	Wu Y, Meitzler JL, Antony S, Juhasz A, Lu J, Jiang G, Liu H, Hollingshead M, Haines DC, Butcher D, et al: Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A. Oncotarget. 7:68412–68433. 2016. View Article : Google Scholar : PubMed/NCBI
60	Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794–798. 1991.PubMed/NCBI
61	Gloire G, Legrand-Poels S and Piette J: NF-kappaB activation by reactive oxygen species: Fifteen years later. Biochem Pharmacol. 72:1493–1505. 2006. View Article : Google Scholar : PubMed/NCBI
62	Jia J, Ye T, Cui P, Hua Q, Zeng H and Zhao D: AP-1 transcription factor mediates VEGF-induced endothelial cell migration and proliferation. Microvasc Res. 105:103–108. 2016. View Article : Google Scholar : PubMed/NCBI
63	Liu JP: Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 13:2091–2104. 1999. View Article : Google Scholar : PubMed/NCBI
64	Reth M: Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol. 3:1129–1134. 2002. View Article : Google Scholar : PubMed/NCBI
65	Kobayashi CI and Suda T: Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol. 227:421–430. 2012. View Article : Google Scholar : PubMed/NCBI
66	Spadafora C: Endogenous reverse transcriptase: A mediator of cell proliferation and differentiation. Cytogenet Genome Res. 105:346–350. 2004. View Article : Google Scholar : PubMed/NCBI
67	Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729–777. 1999. View Article : Google Scholar : PubMed/NCBI
68	Bendas G and Borsig L: Cancer cell adhesion and metastasis: Selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012:6767312012. View Article : Google Scholar : PubMed/NCBI
69	Knelson EH, Nee JC and Blobe GC: Heparan sulfate signaling in cancer. Trends Biochem Sci. 39:277–288. 2014. View Article : Google Scholar : PubMed/NCBI
70	Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG and Blobe GC: Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. J Clin Invest. 124:3016–3031. 2014. View Article : Google Scholar : PubMed/NCBI
71	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
72	Ji P, Zhang Y, Wang SJ, Ge HL, Zhao GP, Xu YC and Wang Y: CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs. Oncol Rep. 35:3293–3302. 2016. View Article : Google Scholar : PubMed/NCBI